Cellectis (NASDAQ:CLLS) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS) in a research report released on Sunday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Cellectis Trading Down 1.9 %

NASDAQ:CLLS opened at $1.80 on Friday. The stock has a market cap of $100.05 million, a PE ratio of -1.48 and a beta of 3.09. Cellectis has a fifty-two week low of $0.96 and a fifty-two week high of $3.77. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.92 and a quick ratio of 1.92. The stock’s 50-day moving average is $2.17 and its two-hundred day moving average is $2.34.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.05. The firm had revenue of $9.50 million for the quarter, compared to the consensus estimate of $6.00 million. Cellectis had a negative net margin of 401.83% and a negative return on equity of 78.90%. As a group, equities research analysts forecast that Cellectis will post -0.54 earnings per share for the current fiscal year.

Institutional Trading of Cellectis

A number of institutional investors have recently bought and sold shares of CLLS. Baillie Gifford & Co. raised its stake in shares of Cellectis by 1.3% during the 1st quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company’s stock worth $2,192,000 after purchasing an additional 10,605 shares in the last quarter. Principal Financial Group Inc. raised its position in Cellectis by 2.9% during the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after acquiring an additional 12,467 shares in the last quarter. XTX Topco Ltd bought a new position in Cellectis during the second quarter valued at approximately $29,000. First Affirmative Financial Network acquired a new stake in Cellectis in the third quarter valued at approximately $45,000. Finally, Long Focus Capital Management LLC grew its position in Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after acquiring an additional 130,000 shares in the last quarter. Institutional investors and hedge funds own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.